Pfizer said Monday that it plans to submit its experimental Lyme disease vaccine to the U.S. Food and Drug Administration (FDA) for approval, even though the drug failed to show conclusively that it was effective at preventing the disease. Pfizer and its partner, French biotech company Valneva, said in a press release that late-stage trial results for the vaccine showed more than 70% efficacy in preventing infection.